カテゴリ： 世界, 消費財/食品, QYResearch

メニエール病治療薬の世界市場2023年：搭乗式酔い薬、吐き気止め薬、利尿薬、その他

■ 英語タイトル：Global Meniere's Disease Medications for Vertigo Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA8814）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA8814
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：85
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[メニエール病治療薬の世界市場2023年：搭乗式酔い薬、吐き気止め薬、利尿薬、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

本調査資料はメニエール病治療薬のグローバル市場について調査・分析し、世界のメニエール病治療薬市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（搭乗式酔い薬、吐き気止め薬、利尿薬、その他）、用途別セグメント分析（病院、クリニック）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Roche、Novartis、Pfizer、Auris Medical、Jubilant Cadista、Otonomy、Sound Pharmaceuticals、WellSpring Pharmaceuticalなどが含まれています。メニエール病治療薬のグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。新型コロナとロシア・ウクライナ戦争の影響は、メニエール病治療薬市場規模を算出する際に考慮しました。

・メニエール病治療薬市場の概要
- 製品の定義
- メニエール病治療薬の種類別セグメント
- 世界のメニエール病治療薬市場規模：タイプ別分析（搭乗式酔い薬、吐き気止め薬、利尿薬、その他）
- メニエール病治療薬の用途別セグメント
- 世界のメニエール病治療薬市場規模：用途別分析（病院、クリニック）
- 世界のメニエール病治療薬市場規模予測（2018年-2029年）
- メニエール病治療薬の平均価格推移（2018年-2029年）
- 前提条件と制限事項

・メーカー別競争状況
- メーカー別市場シェア
- 世界の主要メーカー、業界ランキング分析
- メーカー別平均価格
- メニエール病治療薬市場の競争状況およびトレンド

・メニエール病治療薬の地域別市場規模
- 北米のメニエール病治療薬市場規模（2018年-2029年）
- 米国のメニエール病治療薬市場規模（2018年-2029年）
- ヨーロッパのメニエール病治療薬市場規模（2018年-2029年）
- アジア太平洋のメニエール病治療薬市場規模（2018年-2029年）
- 中国のメニエール病治療薬市場規模（2018年-2029年）
- 日本のメニエール病治療薬市場規模（2018年-2029年）
- 韓国のメニエール病治療薬市場規模（2018年-2029年）
- インドのメニエール病治療薬市場規模（2018年-2029年）
- オーストラリアのメニエール病治療薬市場規模（2018年-2029年）
- 中南米のメニエール病治療薬市場規模（2018年-2029年）
- 中東・アフリカのメニエール病治療薬市場規模（2018年-2029年）

・種類別セグメント：搭乗式酔い薬、吐き気止め薬、利尿薬、その他
- 世界のメニエール病治療薬のタイプ別販売量（2018年-2023年）
- 世界のメニエール病治療薬のタイプ別売上（2018年-2023年）
- 世界のメニエール病治療薬のタイプ別価格

・用途別セグメント：病院、クリニック
- 世界のメニエール病治療薬の用途別販売量（2018年-2023年）
- 世界のメニエール病治療薬の用途別売上（2018年-2023年）
- 世界のメニエール病治療薬の用途別価格

・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向
Roche、Novartis、Pfizer、Auris Medical、Jubilant Cadista、Otonomy、Sound Pharmaceuticals、WellSpring Pharmaceutical

・産業チェーンと販売チャネルの分析
- メニエール病治療薬産業チェーン分析
- メニエール病治療薬の主要原材料
- メニエール病治療薬の販売チャネル
- メニエール病治療薬のディストリビューター
- メニエール病治療薬の主要顧客

・メニエール病治療薬市場ダイナミクス
- メニエール病治療薬の業界動向
- メニエール病治療薬市場の成長ドライバ、課題、阻害要因

・調査の結論

・調査手法と情報源

Highlights
The global Meniere’s Disease Medications for Vertigo market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Meniere’s Disease Medications for Vertigo is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Meniere’s Disease Medications for Vertigo is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Meniere’s Disease Medications for Vertigo include Roche, Novartis, Pfizer, Auris Medical, Jubilant Cadista, Otonomy, Sound Pharmaceuticals and WellSpring Pharmaceutical, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Meniere’s Disease Medications for Vertigo, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Meniere’s Disease Medications for Vertigo.
The Meniere’s Disease Medications for Vertigo market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Meniere’s Disease Medications for Vertigo market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Meniere’s Disease Medications for Vertigo manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Roche
Novartis
Pfizer
Auris Medical
Jubilant Cadista
Otonomy
Sound Pharmaceuticals
WellSpring Pharmaceutical
Segment by Type
Motion Sickness Drugs
Drugs for Nausea
Diuretics
Others
Segment by Application
Hospitals
Clinics
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Meniere’s Disease Medications for Vertigo manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Meniere’s Disease Medications for Vertigo in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Meniere’s Disease Medications for Vertigo Market Overview
1.1 Product Overview and Scope of Meniere’s Disease Medications for Vertigo
1.2 Meniere’s Disease Medications for Vertigo Segment by Type
1.2.1 Global Meniere’s Disease Medications for Vertigo Market Value Comparison by Type (2023-2029)
1.2.2 Motion Sickness Drugs
1.2.3 Drugs for Nausea
1.2.4 Diuretics
1.2.5 Others
1.3 Meniere’s Disease Medications for Vertigo Segment by Application
1.3.1 Global Meniere’s Disease Medications for Vertigo Market Value by Application: (2023-2029)
1.3.2 Hospitals
1.3.3 Clinics
1.4 Global Meniere’s Disease Medications for Vertigo Market Size Estimates and Forecasts
1.4.1 Global Meniere’s Disease Medications for Vertigo Revenue 2018-2029
1.4.2 Global Meniere’s Disease Medications for Vertigo Sales 2018-2029
1.4.3 Global Meniere’s Disease Medications for Vertigo Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Meniere’s Disease Medications for Vertigo Market Competition by Manufacturers
2.1 Global Meniere’s Disease Medications for Vertigo Sales Market Share by Manufacturers (2018-2023)
2.2 Global Meniere’s Disease Medications for Vertigo Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Meniere’s Disease Medications for Vertigo Average Price by Manufacturers (2018-2023)
2.4 Global Meniere’s Disease Medications for Vertigo Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Meniere’s Disease Medications for Vertigo, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Meniere’s Disease Medications for Vertigo, Product Type & Application
2.7 Meniere’s Disease Medications for Vertigo Market Competitive Situation and Trends
2.7.1 Meniere’s Disease Medications for Vertigo Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Meniere’s Disease Medications for Vertigo Players Market Share by Revenue
2.7.3 Global Meniere’s Disease Medications for Vertigo Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Meniere’s Disease Medications for Vertigo Retrospective Market Scenario by Region
3.1 Global Meniere’s Disease Medications for Vertigo Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Meniere’s Disease Medications for Vertigo Global Meniere’s Disease Medications for Vertigo Sales by Region: 2018-2029
3.2.1 Global Meniere’s Disease Medications for Vertigo Sales by Region: 2018-2023
3.2.2 Global Meniere’s Disease Medications for Vertigo Sales by Region: 2024-2029
3.3 Global Meniere’s Disease Medications for Vertigo Global Meniere’s Disease Medications for Vertigo Revenue by Region: 2018-2029
3.3.1 Global Meniere’s Disease Medications for Vertigo Revenue by Region: 2018-2023
3.3.2 Global Meniere’s Disease Medications for Vertigo Revenue by Region: 2024-2029
3.4 North America Meniere’s Disease Medications for Vertigo Market Facts & Figures by Country
3.4.1 North America Meniere’s Disease Medications for Vertigo Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Meniere’s Disease Medications for Vertigo Sales by Country (2018-2029)
3.4.3 North America Meniere’s Disease Medications for Vertigo Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Meniere’s Disease Medications for Vertigo Market Facts & Figures by Country
3.5.1 Europe Meniere’s Disease Medications for Vertigo Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Meniere’s Disease Medications for Vertigo Sales by Country (2018-2029)
3.5.3 Europe Meniere’s Disease Medications for Vertigo Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Meniere’s Disease Medications for Vertigo Market Facts & Figures by Country
3.6.1 Asia Pacific Meniere’s Disease Medications for Vertigo Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Meniere’s Disease Medications for Vertigo Sales by Country (2018-2029)
3.6.3 Asia Pacific Meniere’s Disease Medications for Vertigo Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Meniere’s Disease Medications for Vertigo Market Facts & Figures by Country
3.7.1 Latin America Meniere’s Disease Medications for Vertigo Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Meniere’s Disease Medications for Vertigo Sales by Country (2018-2029)
3.7.3 Latin America Meniere’s Disease Medications for Vertigo Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Meniere’s Disease Medications for Vertigo Market Facts & Figures by Country
3.8.1 Middle East and Africa Meniere’s Disease Medications for Vertigo Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Meniere’s Disease Medications for Vertigo Sales by Country (2018-2029)
3.8.3 Middle East and Africa Meniere’s Disease Medications for Vertigo Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Meniere’s Disease Medications for Vertigo Sales by Type (2018-2029)
4.1.1 Global Meniere’s Disease Medications for Vertigo Sales by Type (2018-2023)
4.1.2 Global Meniere’s Disease Medications for Vertigo Sales by Type (2024-2029)
4.1.3 Global Meniere’s Disease Medications for Vertigo Sales Market Share by Type (2018-2029)
4.2 Global Meniere’s Disease Medications for Vertigo Revenue by Type (2018-2029)
4.2.1 Global Meniere’s Disease Medications for Vertigo Revenue by Type (2018-2023)
4.2.2 Global Meniere’s Disease Medications for Vertigo Revenue by Type (2024-2029)
4.2.3 Global Meniere’s Disease Medications for Vertigo Revenue Market Share by Type (2018-2029)
4.3 Global Meniere’s Disease Medications for Vertigo Price by Type (2018-2029)
5 Segment by Application
5.1 Global Meniere’s Disease Medications for Vertigo Sales by Application (2018-2029)
5.1.1 Global Meniere’s Disease Medications for Vertigo Sales by Application (2018-2023)
5.1.2 Global Meniere’s Disease Medications for Vertigo Sales by Application (2024-2029)
5.1.3 Global Meniere’s Disease Medications for Vertigo Sales Market Share by Application (2018-2029)
5.2 Global Meniere’s Disease Medications for Vertigo Revenue by Application (2018-2029)
5.2.1 Global Meniere’s Disease Medications for Vertigo Revenue by Application (2018-2023)
5.2.2 Global Meniere’s Disease Medications for Vertigo Revenue by Application (2024-2029)
5.2.3 Global Meniere’s Disease Medications for Vertigo Revenue Market Share by Application (2018-2029)
5.3 Global Meniere’s Disease Medications for Vertigo Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Corporation Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Meniere’s Disease Medications for Vertigo Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Roche Meniere’s Disease Medications for Vertigo Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Meniere’s Disease Medications for Vertigo Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Novartis Meniere’s Disease Medications for Vertigo Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Meniere’s Disease Medications for Vertigo Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Pfizer Meniere’s Disease Medications for Vertigo Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Auris Medical
6.4.1 Auris Medical Corporation Information
6.4.2 Auris Medical Description and Business Overview
6.4.3 Auris Medical Meniere’s Disease Medications for Vertigo Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Auris Medical Meniere’s Disease Medications for Vertigo Product Portfolio
6.4.5 Auris Medical Recent Developments/Updates
6.5 Jubilant Cadista
6.5.1 Jubilant Cadista Corporation Information
6.5.2 Jubilant Cadista Description and Business Overview
6.5.3 Jubilant Cadista Meniere’s Disease Medications for Vertigo Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Jubilant Cadista Meniere’s Disease Medications for Vertigo Product Portfolio
6.5.5 Jubilant Cadista Recent Developments/Updates
6.6 Otonomy
6.6.1 Otonomy Corporation Information
6.6.2 Otonomy Description and Business Overview
6.6.3 Otonomy Meniere’s Disease Medications for Vertigo Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Otonomy Meniere’s Disease Medications for Vertigo Product Portfolio
6.6.5 Otonomy Recent Developments/Updates
6.7 Sound Pharmaceuticals
6.6.1 Sound Pharmaceuticals Corporation Information
6.6.2 Sound Pharmaceuticals Description and Business Overview
6.6.3 Sound Pharmaceuticals Meniere’s Disease Medications for Vertigo Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Sound Pharmaceuticals Meniere’s Disease Medications for Vertigo Product Portfolio
6.7.5 Sound Pharmaceuticals Recent Developments/Updates
6.8 WellSpring Pharmaceutical
6.8.1 WellSpring Pharmaceutical Corporation Information
6.8.2 WellSpring Pharmaceutical Description and Business Overview
6.8.3 WellSpring Pharmaceutical Meniere’s Disease Medications for Vertigo Sales, Revenue and Gross Margin (2018-2023)
6.8.4 WellSpring Pharmaceutical Meniere’s Disease Medications for Vertigo Product Portfolio
6.8.5 WellSpring Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Meniere’s Disease Medications for Vertigo Industry Chain Analysis
7.2 Meniere’s Disease Medications for Vertigo Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Meniere’s Disease Medications for Vertigo Production Mode & Process
7.4 Meniere’s Disease Medications for Vertigo Sales and Marketing
7.4.1 Meniere’s Disease Medications for Vertigo Sales Channels
7.4.2 Meniere’s Disease Medications for Vertigo Distributors
7.5 Meniere’s Disease Medications for Vertigo Customers
8 Meniere’s Disease Medications for Vertigo Market Dynamics
8.1 Meniere’s Disease Medications for Vertigo Industry Trends
8.2 Meniere’s Disease Medications for Vertigo Market Drivers
8.3 Meniere’s Disease Medications for Vertigo Market Challenges
8.4 Meniere’s Disease Medications for Vertigo Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Tables
Table 1. Global Meniere's Disease Medications for Vertigo Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Meniere's Disease Medications for Vertigo Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Meniere's Disease Medications for Vertigo Market Competitive Situation by Manufacturers in 2022
Table 4. Global Meniere's Disease Medications for Vertigo Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Meniere's Disease Medications for Vertigo Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Meniere's Disease Medications for Vertigo Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Meniere's Disease Medications for Vertigo Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Meniere's Disease Medications for Vertigo Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Meniere's Disease Medications for Vertigo, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Meniere's Disease Medications for Vertigo, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Meniere's Disease Medications for Vertigo, Product Type & Application
Table 12. Global Key Manufacturers of Meniere's Disease Medications for Vertigo, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Meniere's Disease Medications for Vertigo by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Meniere's Disease Medications for Vertigo as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Meniere's Disease Medications for Vertigo Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Meniere's Disease Medications for Vertigo Sales by Region (2018-2023) & (K Units)
Table 18. Global Meniere's Disease Medications for Vertigo Sales Market Share by Region (2018-2023)
Table 19. Global Meniere's Disease Medications for Vertigo Sales by Region (2024-2029) & (K Units)
Table 20. Global Meniere's Disease Medications for Vertigo Sales Market Share by Region (2024-2029)
Table 21. Global Meniere's Disease Medications for Vertigo Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Meniere's Disease Medications for Vertigo Revenue Market Share by Region (2018-2023)
Table 23. Global Meniere's Disease Medications for Vertigo Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Meniere's Disease Medications for Vertigo Revenue Market Share by Region (2024-2029)
Table 25. North America Meniere's Disease Medications for Vertigo Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Meniere's Disease Medications for Vertigo Sales by Country (2018-2023) & (K Units)
Table 27. North America Meniere's Disease Medications for Vertigo Sales by Country (2024-2029) & (K Units)
Table 28. North America Meniere's Disease Medications for Vertigo Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Meniere's Disease Medications for Vertigo Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Meniere's Disease Medications for Vertigo Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Meniere's Disease Medications for Vertigo Sales by Country (2018-2023) & (K Units)
Table 32. Europe Meniere's Disease Medications for Vertigo Sales by Country (2024-2029) & (K Units)
Table 33. Europe Meniere's Disease Medications for Vertigo Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Meniere's Disease Medications for Vertigo Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Meniere's Disease Medications for Vertigo Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Meniere's Disease Medications for Vertigo Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Meniere's Disease Medications for Vertigo Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Meniere's Disease Medications for Vertigo Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Meniere's Disease Medications for Vertigo Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Meniere's Disease Medications for Vertigo Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Meniere's Disease Medications for Vertigo Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Meniere's Disease Medications for Vertigo Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Meniere's Disease Medications for Vertigo Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Meniere's Disease Medications for Vertigo Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Meniere's Disease Medications for Vertigo Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Meniere's Disease Medications for Vertigo Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Meniere's Disease Medications for Vertigo Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Meniere's Disease Medications for Vertigo Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Meniere's Disease Medications for Vertigo Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Meniere's Disease Medications for Vertigo Sales (K Units) by Type (2018-2023)
Table 51. Global Meniere's Disease Medications for Vertigo Sales (K Units) by Type (2024-2029)
Table 52. Global Meniere's Disease Medications for Vertigo Sales Market Share by Type (2018-2023)
Table 53. Global Meniere's Disease Medications for Vertigo Sales Market Share by Type (2024-2029)
Table 54. Global Meniere's Disease Medications for Vertigo Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Meniere's Disease Medications for Vertigo Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Meniere's Disease Medications for Vertigo Revenue Market Share by Type (2018-2023)
Table 57. Global Meniere's Disease Medications for Vertigo Revenue Market Share by Type (2024-2029)
Table 58. Global Meniere's Disease Medications for Vertigo Price (US$/Unit) by Type (2018-2023)
Table 59. Global Meniere's Disease Medications for Vertigo Price (US$/Unit) by Type (2024-2029)
Table 60. Global Meniere's Disease Medications for Vertigo Sales (K Units) by Application (2018-2023)
Table 61. Global Meniere's Disease Medications for Vertigo Sales (K Units) by Application (2024-2029)
Table 62. Global Meniere's Disease Medications for Vertigo Sales Market Share by Application (2018-2023)
Table 63. Global Meniere's Disease Medications for Vertigo Sales Market Share by Application (2024-2029)
Table 64. Global Meniere's Disease Medications for Vertigo Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Meniere's Disease Medications for Vertigo Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Meniere's Disease Medications for Vertigo Revenue Market Share by Application (2018-2023)
Table 67. Global Meniere's Disease Medications for Vertigo Revenue Market Share by Application (2024-2029)
Table 68. Global Meniere's Disease Medications for Vertigo Price (US$/Unit) by Application (2018-2023)
Table 69. Global Meniere's Disease Medications for Vertigo Price (US$/Unit) by Application (2024-2029)
Table 70. Roche Corporation Information
Table 71. Roche Description and Business Overview
Table 72. Roche Meniere's Disease Medications for Vertigo Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Roche Meniere's Disease Medications for Vertigo Product
Table 74. Roche Recent Developments/Updates
Table 75. Novartis Corporation Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Meniere's Disease Medications for Vertigo Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Novartis Meniere's Disease Medications for Vertigo Product
Table 79. Novartis Recent Developments/Updates
Table 80. Pfizer Corporation Information
Table 81. Pfizer Description and Business Overview
Table 82. Pfizer Meniere's Disease Medications for Vertigo Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Pfizer Meniere's Disease Medications for Vertigo Product
Table 84. Pfizer Recent Developments/Updates
Table 85. Auris Medical Corporation Information
Table 86. Auris Medical Description and Business Overview
Table 87. Auris Medical Meniere's Disease Medications for Vertigo Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Auris Medical Meniere's Disease Medications for Vertigo Product
Table 89. Auris Medical Recent Developments/Updates
Table 90. Jubilant Cadista Corporation Information
Table 91. Jubilant Cadista Description and Business Overview
Table 92. Jubilant Cadista Meniere's Disease Medications for Vertigo Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Jubilant Cadista Meniere's Disease Medications for Vertigo Product
Table 94. Jubilant Cadista Recent Developments/Updates
Table 95. Otonomy Corporation Information
Table 96. Otonomy Description and Business Overview
Table 97. Otonomy Meniere's Disease Medications for Vertigo Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Otonomy Meniere's Disease Medications for Vertigo Product
Table 99. Otonomy Recent Developments/Updates
Table 100. Sound Pharmaceuticals Corporation Information
Table 101. Sound Pharmaceuticals Description and Business Overview
Table 102. Sound Pharmaceuticals Meniere's Disease Medications for Vertigo Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Sound Pharmaceuticals Meniere's Disease Medications for Vertigo Product
Table 104. Sound Pharmaceuticals Recent Developments/Updates
Table 105. WellSpring Pharmaceutical Corporation Information
Table 106. WellSpring Pharmaceutical Description and Business Overview
Table 107. WellSpring Pharmaceutical Meniere's Disease Medications for Vertigo Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. WellSpring Pharmaceutical Meniere's Disease Medications for Vertigo Product
Table 109. WellSpring Pharmaceutical Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. Meniere's Disease Medications for Vertigo Distributors List
Table 113. Meniere's Disease Medications for Vertigo Customers List
Table 114. Meniere's Disease Medications for Vertigo Market Trends
Table 115. Meniere's Disease Medications for Vertigo Market Drivers
Table 116. Meniere's Disease Medications for Vertigo Market Challenges
Table 117. Meniere's Disease Medications for Vertigo Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Meniere's Disease Medications for Vertigo
Figure 2. Global Meniere's Disease Medications for Vertigo Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Meniere's Disease Medications for Vertigo Market Share by Type in 2022 & 2029
Figure 4. Motion Sickness Drugs Product Picture
Figure 5. Drugs for Nausea Product Picture
Figure 6. Diuretics Product Picture
Figure 7. Others Product Picture
Figure 8. Global Meniere's Disease Medications for Vertigo Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 9. Global Meniere's Disease Medications for Vertigo Market Share by Application in 2022 & 2029
Figure 10. Hospitals
Figure 11. Clinics
Figure 12. Global Meniere's Disease Medications for Vertigo Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Meniere's Disease Medications for Vertigo Market Size (2018-2029) & (US$ Million)
Figure 14. Global Meniere's Disease Medications for Vertigo Sales (2018-2029) & (K Units)
Figure 15. Global Meniere's Disease Medications for Vertigo Average Price (US$/Unit) & (2018-2029)
Figure 16. Meniere's Disease Medications for Vertigo Report Years Considered
Figure 17. Meniere's Disease Medications for Vertigo Sales Share by Manufacturers in 2022
Figure 18. Global Meniere's Disease Medications for Vertigo Revenue Share by Manufacturers in 2022
Figure 19. The Global 5 and 10 Largest Meniere's Disease Medications for Vertigo Players: Market Share by Revenue in 2022
Figure 20. Meniere's Disease Medications for Vertigo Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 21. Global Meniere's Disease Medications for Vertigo Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 22. North America Meniere's Disease Medications for Vertigo Sales Market Share by Country (2018-2029)
Figure 23. North America Meniere's Disease Medications for Vertigo Revenue Market Share by Country (2018-2029)
Figure 24. United States Meniere's Disease Medications for Vertigo Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Canada Meniere's Disease Medications for Vertigo Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Europe Meniere's Disease Medications for Vertigo Sales Market Share by Country (2018-2029)
Figure 27. Europe Meniere's Disease Medications for Vertigo Revenue Market Share by Country (2018-2029)
Figure 28. Germany Meniere's Disease Medications for Vertigo Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. France Meniere's Disease Medications for Vertigo Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. U.K. Meniere's Disease Medications for Vertigo Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Italy Meniere's Disease Medications for Vertigo Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Russia Meniere's Disease Medications for Vertigo Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Asia Pacific Meniere's Disease Medications for Vertigo Sales Market Share by Region (2018-2029)
Figure 34. Asia Pacific Meniere's Disease Medications for Vertigo Revenue Market Share by Region (2018-2029)
Figure 35. China Meniere's Disease Medications for Vertigo Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Japan Meniere's Disease Medications for Vertigo Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. South Korea Meniere's Disease Medications for Vertigo Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. India Meniere's Disease Medications for Vertigo Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Australia Meniere's Disease Medications for Vertigo Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. China Taiwan Meniere's Disease Medications for Vertigo Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Indonesia Meniere's Disease Medications for Vertigo Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Thailand Meniere's Disease Medications for Vertigo Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Malaysia Meniere's Disease Medications for Vertigo Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Latin America Meniere's Disease Medications for Vertigo Sales Market Share by Country (2018-2029)
Figure 45. Latin America Meniere's Disease Medications for Vertigo Revenue Market Share by Country (2018-2029)
Figure 46. Mexico Meniere's Disease Medications for Vertigo Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Brazil Meniere's Disease Medications for Vertigo Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Argentina Meniere's Disease Medications for Vertigo Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Meniere's Disease Medications for Vertigo Sales Market Share by Country (2018-2029)
Figure 50. Middle East & Africa Meniere's Disease Medications for Vertigo Revenue Market Share by Country (2018-2029)
Figure 51. Turkey Meniere's Disease Medications for Vertigo Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Saudi Arabia Meniere's Disease Medications for Vertigo Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. UAE Meniere's Disease Medications for Vertigo Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Global Sales Market Share of Meniere's Disease Medications for Vertigo by Type (2018-2029)
Figure 55. Global Revenue Market Share of Meniere's Disease Medications for Vertigo by Type (2018-2029)
Figure 56. Global Meniere's Disease Medications for Vertigo Price (US$/Unit) by Type (2018-2029)
Figure 57. Global Sales Market Share of Meniere's Disease Medications for Vertigo by Application (2018-2029)
Figure 58. Global Revenue Market Share of Meniere's Disease Medications for Vertigo by Application (2018-2029)
Figure 59. Global Meniere's Disease Medications for Vertigo Price (US$/Unit) by Application (2018-2029)
Figure 60. Meniere's Disease Medications for Vertigo Value Chain
Figure 61. Meniere's Disease Medications for Vertigo Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • めまい治療薬のグローバル市場展望 2023年-2029年：経口、注射
  • マイボーム腺機能不全治療薬のグローバル市場展望 2023年-2029年：経口、外用
  • 処方鎮痛薬のグローバル市場展望 2023年-2029年：処方薬 NSAIDs、オピオイド、抗てんかん薬、抗うつ薬、その他
  • 皮膚科処方薬のグローバル市場展望 2023年-2029年：経口、局所
  • 放射線緊急治療薬のグローバル市場展望 2023年-2029年：ヨウ化カリウム（KI）、プルシアンブルー、DTPA（ジエチレントリアミン五酢酸）、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA8814 )"メニエール病治療薬の世界市場2023年：搭乗式酔い薬、吐き気止め薬、利尿薬、その他" (英文：Global Meniere's Disease Medications for Vertigo Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。